Hh Signaling Antagonist VII, JK184 is an imidazopyridine compound that inhibits the Hedgehog (Hh) signaling pathway. JK184 is described to directly interact with tubulin subunits and prevent their polymerization into filaments, affecting the Hh pathway by destabilizing microtubules and modulating the microtubule-dependent mechanisms regulating function of the Gli transcription factors. JK184 also inhibits ADH7 (alcohol dehydrogenase 7), a function suggested to be ancillary to the effects of JK184 on microtubules and the Hh pathway.
1. Lee, Jongkook., et al., 2007. A small-molecule antagonist of the hedgehog signaling pathway. Chembiochem : a European journal of chemical biology. 8(16): 1916-9. PMID: 17886323
2. Cupido, Tommaso., et al., 2009. The imidazopyridine derivative JK184 reveals dual roles for microtubules in Hedgehog signaling. Angewandte Chemie (International ed. in English). 48(13): 2321-4. PMID: 19222062
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.